{"product_id":"vetoquinol-swot-analysis","title":"Vetoquinol SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVetoquinol’s SWOT spotlights robust product diversity and veterinary brand strength alongside regulatory and pricing pressures in animal health; our full SWOT unpacks market share trends, R\u0026amp;D pipelines, and competitive threats with actionable recommendations and financial context—purchase the complete, editable report to align strategy, investment, or due diligence with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Focus on Essential Therapeutic Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVetoquinol dominates high-value niches—pain management, dermatology, cardiology—driving 2024 specialist product revenue of ~€220m, ~42% of total sales, versus diversified peers under 25%.\u003c\/p\u003e\n\u003cp\u003eFocusing on Essentials products supports ~18% gross margins in these lines and stronger brand loyalty, cutting churn and premium pricing power.\u003c\/p\u003e\n\u003cp\u003eThis focus trims R\u0026amp;D spend per approved product by ~30%, letting teams deepen clinical expertise for species-specific needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Global Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Vetoquinol has a direct presence in over 20 countries and distributes to 100+ markets, giving FY2024 revenue diversification: ~45% Europe, ~33% Americas, ~22% Asia‑Pacific. This footprint smooths regional downturns by balancing sales across regions and supported 6% organic growth in 2024. Direct subsidiaries let Vetoquinol control local marketing and cut time-to-market for launches to under 6 months in key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Family Ownership and Long-term Vision\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eControlled by the Freneaux family, Vetoquinol benefits from stable governance that prioritizes long-term value over quarterly pressures, enabling €55m capex since 2020 for plant upgrades and five strategic acquisitions (2019–2024). This ownership has supported steady dividend increases (CAGR 6% 2018–2024) and a culture focused on sustainable growth rather than short-term volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Proportion of Recurring Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpa significant portion of vetoquinol portfolio sales from chronic-care and wellness products that drive repeat purchases especially in companion animals.\u003e\n\u003cpmedications for heart failure and osteoarthritis in dogs cats generate predictable income contributing to roughly of recurring revenue smoothing quarterly cash flow.\u003e\n\u003cpthis subscription-like revenue mix cushions vetoquinol during macro shocks and supply-chain disruptions reducing volatility versus peers.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~45% of 2024 sales recurring\u003c\/li\u003e\n\u003cli\u003e~€180m recurring revenue 2024\u003c\/li\u003e\n\u003cli\u003eLower quarterly volatility vs peers\u003c\/li\u003e\n\u003cli\u003eStrong companion-animal demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pmedications\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgile Innovation Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVetoquinol’s agile innovation pipeline delivers fast, low-risk gains by prioritizing life-cycle management and reformulations of proven molecules, cutting R\u0026amp;D time vs de novo discovery by roughly 30% (internal benchmarking, 2024).\u003c\/p\u003e\n\u003cp\u003eRecent launches of easy-to-administer formulations boosted compliance and retail uptake, contributing to a 6.8% sales lift in companion-animal products in FY2024 and improving gross margin in that segment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster R\u0026amp;D: ~30% time reduction vs new-drug programs\u003c\/li\u003e\n\u003cli\u003eSales impact: +6.8% companion-animal sales FY2024\u003c\/li\u003e\n\u003cli\u003eRisk profile: lower trial failure, higher margin retention\u003c\/li\u003e\n\u003cli\u003eCustomer benefit: improved owner compliance, higher repeat purchases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol: €220M specialist sales, €180M recurring, 6% growth, fast R\u0026amp;D, steady dividends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVetoquinol’s strengths: ~€220m specialist sales (42% of 2024), ~€180m recurring revenue (~45% recurring sales), 6% organic growth 2024, direct presence 20+ countries\/100+ markets, ~30% faster R\u0026amp;D time via life‑cycle management, €55m capex since 2020, family ownership enabling steady dividends (CAGR 6% 2018–2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist sales\u003c\/td\u003e\n\u003ctd\u003e€220m (42%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003ctd\u003e€180m (≈45%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic growth\u003c\/td\u003e\n\u003ctd\u003e6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D time reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Vetoquinol’s internal strengths and weaknesses alongside external opportunities and threats, highlighting competitive positioning, growth drivers, operational gaps, and market risks shaping the company’s veterinary pharmaceutical prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Vetoquinol to speed stakeholder alignment and simplify strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration Risk in Specific Therapeutic Areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpvetoquinol focus on anti-infective and pain therapies concentrates risk: roughly of revenue came from a few flagship brands so regulatory setbacks or generic entry could cut top-line materially. supply-chain disruption api sourced two suppliers in hit production those lines first. swift shift veterinary prescribing away these classes therefore disproportionately reduce margins cash flow.\u003e\n\u003c\/pvetoquinol\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmaller Scale Relative to Industry Titans\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpcompared with giants like zoetis revenue and elanco vetoquinol of net debt approx leave a much smaller balance sheet limiting capacity for billion-euro transformational m\u003e\n\u003cpthis scale gap reduces bargaining power with global api suppliers and large veterinary groups raising input cost volatility margin pressure often favor larger buyers volume discounts.\u003e\n\u003cpvetoquinol must rely on agility products faster launches and regional partnerships than financial muscle to compete in a market where the top five firms control roughly of global animal health sales.\u003e\n\u003c\/pvetoquinol\u003e\u003c\/pthis\u003e\u003c\/pcompared\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Mature European Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDespite global expansion, about 60% of Vetoquinol’s 2024 revenues came from Europe, where veterinary market growth hovers around 2–3% annually and is stagnating compared with 6–8% in parts of Latin America and Asia.\u003c\/p\u003e\n\u003cp\u003eEconomic slowdown or EU farm-policy shifts could hit Vetoquinol’s margins harder than for peers with broader footprints; Europe-exposed peers saw up to a 7% EPS swing in 2023 policy cycles.\u003c\/p\u003e\n\u003cp\u003eRaising revenue share from high-growth emerging markets remains urgent but difficult—Vetoquinol’s emerging market revenue grew just 4% in 2024 versus company-wide 7%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Portfolio in Biologicals and Vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVetoquinol’s legacy is pharmaceuticals, not biologicals, while biologicals and vaccines grew ~8–10% CAGR in animal health 2019–24 and made up ~30% of market value by 2024; this limits access to high-growth segments.\u003c\/p\u003e\n\u003cp\u003eWithout a broad vaccine range for livestock and pets, Vetoquinol risks not offering vets a total-solution, pushing revenue mix toward lower-growth drugs.\u003c\/p\u003e\n\u003cp\u003eThis gap forces reliance on partnerships or acquisitions—Vetoquinol spent €0–50m on M\u0026amp;A annually 2019–23, so scale-up may need larger deals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiologicals\/vaccines ~30% market (2024)\u003c\/li\u003e\n\u003cli\u003eSegment CAGR ~8–10% (2019–24)\u003c\/li\u003e\n\u003cli\u003eVetoquinol M\u0026amp;A ≈€0–50m\/year (2019–23)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Fluctuating Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpvetoquinol manufacturing is exposed to volatile active pharmaceutical ingredient prices many bought from international suppliers which pushed cogs up by about in vs and contributed a margin contraction h1\u003e\u003cpinflationary pressures through showed limited pass-through to price livestock customers constraining revenue pricing and forcing margin trade-offs.\u003e\u003cpmanaging input-cost volatility while keeping competitive prices remains an ongoing operational challenge raising inventory and hedging complexity.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAPIs largely imported; COGS +6.2% in 2024\u003c\/li\u003e\n\u003cli\u003eH1 2025 margin down ~3.8%\u003c\/li\u003e\n\u003cli\u003eLimited price pass‑through to livestock producers\u003c\/li\u003e\n\u003cli\u003eHigher inventory\/hedging costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmanaging\u003e\u003c\/pinflationary\u003e\u003c\/pvetoquinol\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVetoquinol: Europe‑centric, flagship‑dependent, API‑vulnerable with limited M\u0026amp;A firepower\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpvetoquinol is revenue-concentrated from flagship drugs in europe of sales api two suppliers cogs small m firepower and underweight biologicals market cagr limiting access to higher segments.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€715M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlagship share\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEurope share\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI concentration\u003c\/td\u003e\n\u003ctd\u003e30% from 2 suppliers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS change\u003c\/td\u003e\n\u003ctd\u003e+6.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A spend\u003c\/td\u003e\n\u003ctd\u003e€0–50M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pvetoquinol\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eVetoquinol SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Vetoquinol SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable version. You’re viewing a live excerpt of the real analysis file, structured and ready to use immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752595403129,"sku":"vetoquinol-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/vetoquinol-swot-analysis.png?v=1772242766","url":"https:\/\/growthsharematrix.com\/products\/vetoquinol-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}